bumetanide has been researched along with Neurodevelopmental Disorders in 3 studies
Neurodevelopmental Disorders: These are a group of conditions with onset in the developmental period. The disorders typically manifest early in development, often before the child enters grade school, and are characterized by developmental deficits that produce impairments of personal, social, academic, or occupational functioning. (From DSM-5).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bumetanide is a selective NKCC1 chloride importer antagonist which is being repurposed as a mechanism-based treatment for neurodevelopmental disorders (NDDs)." | 9.51 | Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol. ( Bruining, H; Cristian, G; Geertjens, L; Haspels, E; Ramautar, J; van der Wilt, GJ; Verhage, M, 2022) |
| "Bumetanide treatment is a potential treatment to alleviate the behavioral burden and quality of life associated with TSC." | 6.94 | Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study. ( Bruining, H; Jansen, FE; Oranje, B; Scheepers, FE; Sprengers, JJ; van Andel, DM, 2020) |
| "Bumetanide is a selective NKCC1 chloride importer antagonist which is being repurposed as a mechanism-based treatment for neurodevelopmental disorders (NDDs)." | 5.51 | Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol. ( Bruining, H; Cristian, G; Geertjens, L; Haspels, E; Ramautar, J; van der Wilt, GJ; Verhage, M, 2022) |
| "Before we elaborate on the postulated discrepancies between our trial and previous bumetanide in autism spectrum disorder (ASD) trials, we would like to acknowledge the crucial pioneering work on the γ-aminobutyric acid (GABA) developmental sequence by Dr." | 4.02 | Dr. Sprengers et al. Reply. ( Bruining, H; Sprengers, JJ; van Andel, DM, 2021) |
| "Bumetanide treatment is a potential treatment to alleviate the behavioral burden and quality of life associated with TSC." | 2.94 | Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study. ( Bruining, H; Jansen, FE; Oranje, B; Scheepers, FE; Sprengers, JJ; van Andel, DM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geertjens, L | 1 |
| Cristian, G | 1 |
| Haspels, E | 1 |
| Ramautar, J | 1 |
| van der Wilt, GJ | 1 |
| Verhage, M | 1 |
| Bruining, H | 3 |
| van Andel, DM | 2 |
| Sprengers, JJ | 2 |
| Oranje, B | 1 |
| Scheepers, FE | 1 |
| Jansen, FE | 1 |
2 trials available for bumetanide and Neurodevelopmental Disorders
| Article | Year |
|---|---|
Single-case experimental designs for bumetanide across neurodevelopmental disorders: BUDDI protocol.
Topics: Bumetanide; Child; Cohort Studies; Humans; Neurodevelopmental Disorders; Research Design; Treatment | 2022 |
Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study.
Topics: Adolescent; Autism Spectrum Disorder; Bumetanide; Child; Disease Susceptibility; Duration of Therapy | 2020 |
1 other study available for bumetanide and Neurodevelopmental Disorders
| Article | Year |
|---|---|
Dr. Sprengers et al. Reply.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Bumetanide; gamma-Aminobutyric Acid; Humans; N | 2021 |